免疫检查点阻断通过扩增效应 CD8⁺ T 细胞克隆增强淋巴细胞清除性化疗诱导的抗肿瘤免疫
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Cutaneous melanoma in older patients.
Cutaneous melanoma in older patients.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
在老年 CMM 患者中,CMM 的临床病理表现呈现出独特特征。目前的结果为优化二级预防策略以及完善针对老年患者的诊断-治疗方案提供了关键信息。
在工业化国家,人口老龄化正在稳步上升。皮肤恶性黑色素瘤(CMM)的发病率在老年人中最高。本研究聚焦于老年患者CMM的临床病理特征及诊断-治疗性能指标。
这项基于人群的回顾性队列研究纳入了2017年威尼托大区癌症登记处(意大利东北部)记录的1,368例新发CMM。高龄受试者定义为≥80岁,老年定义为65-79岁,成人定义为<65岁。变量对之间的关联强度采用Cramer's-V检验。以年龄组为因变量,以临床病理CMM特征为协变量,拟合有序logistic回归。在三个年龄组中,临床性能指标均采用Clopper-Pearson精确法计算。
与年龄小于80岁的患者(1,187例)相比,老年患者(181例;13.2%)的CMM具有不同的地形分布,溃疡发生率更高(43.3%对12.7%;p < 0.001),Breslow指数更高(p < 0.001),TIL(肿瘤浸润淋巴细胞)发生率更低(64.4%对76.5%,p < 0.01),且临床就诊时pTNM分期更晚(p < 0.001)。前哨淋巴结阳性的老年患者接受前哨淋巴结活检和淋巴结清扫术的频率更低(分别为60.0%对94.2%和44.4%对85.5%;p < 0.001)。
In industrialized countries, the aging population is steadily rising. The incidence of cutaneous malignant melanoma (CMM) is highest in old people. This study focuses on the clinicopathological profile of CMM and indicators of diagnostic-therapeutic performance in older patients.
This retrospective population-based cohort study included 1,368 incident CMM, as recorded in 2017 by the Regional Veneto Cancer Registry (Northeast Italy). Older subjects were defined as ≥ 80, old as 65-79, and adults as < 65 years of age. The strength of association between pairs of variables was tested by Cramer's-V. Using age groups as the dependent variable, ordered logistic regression was fitted using the clinicopathological CMM profiles as covariates. In each of the three age-groups, the indicators of clinical performance were computed using the Clopper-Pearson exact method.
Compared to patients aged younger than 80 years (1,187), CMM in older patients (181; 13.2%) featured different CMM topography, a higher prevalence of ulcers (43.3% versus 12.7%; p < 0.001), a higher Breslow index (p < 0.001), a lower prevalence of tumor-infiltrating lymphocytes (64.4% versus 76.5%, p < 0.01), and a more advanced pTNM stage at clinical presentation (p < 0.001). Elderly patients with a positive sentinel-lymph node less frequently underwent sentinel- lymph node biopsy and lymphadenectomy (60.0% versus 94.2%, and 44.4% versus 85.5%, respectively; p < 0.001).
In older CMM patients, the clinicopathological presentation of CMM shows a distinctive profile. The present results provide critical information to optimize secondary prevention strategies and refine diagnostic-therapeutic procedures tailored to older patients.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。